Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer
- PMID: 21364029
- PMCID: PMC3064558
- DOI: 10.1158/1055-9965.EPI-10-0974
Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer
Abstract
Background: Triple-negative breast cancer, characterized by a lack of hormone receptor and HER2 expression, is associated with a particularly poor prognosis. Focusing on potentially modifiable breast cancer risk factors, we examined the relationship between body size, physical activity, and triple-negative disease risk.
Methods: Using data from 155,723 women enrolled in the Women's Health Initiative (median follow-up, 7.9 years), we assessed associations between baseline body mass index (BMI), BMI in earlier adulthood, waist and hip circumference, waist-hip ratio, recreational physical activity, and risk of triple-negative (n=307) and estrogen receptor-positive (ER+, n=2,610) breast cancers.
Results: Women in the highest versus lowest BMI quartile had 1.35-fold (95% CI, 0.92-1.99) and 1.39-fold (95% CI, 1.22-1.58) increased risks of triple-negative and ER+ breast cancers, respectively. Waist and hip circumferences were positively associated with risk of ER+ breast cancer (Ptrend=0.01 for both measures) but were not associated with triple-negative breast cancer. Compared with women who reported no recreational physical activity, women in the highest activity tertile had similarly lower risks of triple-negative and ER+ breast cancers (HR=0.77; 95% CI, 0.51-1.13; and HR=0.85; 95% CI, 0.74-0.98, respectively).
Conclusions: Despite biological and clinical differences, triple-negative and ER+ breast cancers are similarly associated with BMI and recreational physical activity in postmenopausal women. The biological mechanisms underlying these similarities are uncertain and these modest associations require further investigation.
Impact: If confirmed, these results suggest potential ways postmenopausal women might modify their risk of both ER+ and triple-negative breast cancers.
©2011 AACR.
Similar articles
-
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.J Natl Cancer Inst. 2011 Mar 16;103(6):470-7. doi: 10.1093/jnci/djr030. Epub 2011 Feb 23. J Natl Cancer Inst. 2011. PMID: 21346227 Free PMC article.
-
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.Breast Cancer Res. 2012 May 14;14(3):R76. doi: 10.1186/bcr3186. Breast Cancer Res. 2012. PMID: 22583394 Free PMC article.
-
Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.Breast Cancer Res Treat. 2016 Jun;157(3):545-54. doi: 10.1007/s10549-016-3825-9. Epub 2016 May 24. Breast Cancer Res Treat. 2016. PMID: 27220749 Free PMC article.
-
Triple negative tumours: a critical review.Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x. Histopathology. 2008. PMID: 18171422 Review.
-
Optimizing treatment for HER2-positive HR-positive breast cancer.Cancer Treat Rev. 2023 Apr;115:102529. doi: 10.1016/j.ctrv.2023.102529. Epub 2023 Feb 28. Cancer Treat Rev. 2023. PMID: 36921556 Review.
Cited by
-
Tumor mechanics and metabolic dysfunction.Free Radic Biol Med. 2015 Feb;79:269-80. doi: 10.1016/j.freeradbiomed.2014.11.020. Epub 2014 Dec 19. Free Radic Biol Med. 2015. PMID: 25532934 Free PMC article. Review.
-
Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.Breast Cancer Res Treat. 2013 Jan;137(2):579-87. doi: 10.1007/s10549-012-2365-1. Epub 2012 Dec 9. Breast Cancer Res Treat. 2013. PMID: 23224237 Free PMC article.
-
Disparities in Breast Cancer Care-How Factors Related to Prevention, Diagnosis, and Treatment Drive Inequity.Healthcare (Basel). 2024 Feb 12;12(4):462. doi: 10.3390/healthcare12040462. Healthcare (Basel). 2024. PMID: 38391837 Free PMC article. Review.
-
Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.Breast Cancer Res. 2013;15(4):R59. doi: 10.1186/bcr3453. Breast Cancer Res. 2013. PMID: 23880059 Free PMC article.
-
A Comparative Analysis of Body Mass Index with Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Pre- and Postmenopausal Breast Cancer Patients.J Midlife Health. 2020 Oct-Dec;11(4):210-216. doi: 10.4103/jmh.JMH_97_20. Epub 2021 Jan 21. J Midlife Health. 2020. PMID: 33767561 Free PMC article.
References
-
- Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502. - PubMed
-
- Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–1728. - PubMed
-
- Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113:357–370. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 32105-6/PHS HHS/United States
- N01 WH032105/WH/WHI NIH HHS/United States
- 32100-2/PHS HHS/United States
- 24152/PHS HHS/United States
- 42129-32/PHS HHS/United States
- T32 CA009168/CA/NCI NIH HHS/United States
- 32118-32119/PHS HHS/United States
- 32122/PHS HHS/United States
- N01 WH044221/WH/WHI NIH HHS/United States
- N01 WH32115/WH/WHI NIH HHS/United States
- T32 CA09168/CA/NCI NIH HHS/United States
- R25 CA094880-10/CA/NCI NIH HHS/United States
- N01 WH042107/WH/WHI NIH HHS/United States
- 42107-26/PHS HHS/United States
- 32115/PHS HHS/United States
- N01 WH032100/WH/WHI NIH HHS/United States
- N01 WH032111/WH/WHI NIH HHS/United States
- N01 WH032122/WH/WHI NIH HHS/United States
- N01 WH032118/WH/WHI NIH HHS/United States
- R25 CA094880/CA/NCI NIH HHS/United States
- R25-CA-94880/CA/NCI NIH HHS/United States
- 32108-9/PHS HHS/United States
- N01 WH022110-024/WH/WHI NIH HHS/United States
- T32 CA009168-30/CA/NCI NIH HHS/United States
- N01 WH032108/WH/WHI NIH HHS/United States
- 44221/PHS HHS/United States
- 32111-13/PHS HHS/United States
- N01 WH032119/WH/WHI NIH HHS/United States
- N01 WH024152/WH/WHI NIH HHS/United States
- N01WH22110/WH/WHI NIH HHS/United States
- N01 WH042129/WH/WHI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous